Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma
Condition(s) studied
Investigational drug(s) / intervention(s)
Endoscopic Ultrasound-Guided Ethanol Ablation: Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.
Study summary
This is a prospective, single-center, single-arm study evaluating endoscopic ultrasound-guided ethanol ablation for left-sided aldosterone-producing adenoma. Eligible participants will receive the ablation procedure and be followed for safety, imaging response, biochemical remission, and clinical remission. The study is expected to enroll 30 participants.
Eligibility
Primary outcome measure(s)
- Procedure-related major adverse events — Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation
Assessment of predefined procedure-related major adverse events occurring within 24-48 hours after endoscopic ultrasound-guided ethanol ablation, including imaging-confirmed major bleeding, gastrointestinal perforation, major organ infarction, and hypertensive urgency or emergency (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | Choongqing |
More Chongqing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07700472 on ClinicalTrials.gov ↗ ← All trials in China